Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Sponsor
Di Wu
Study ID
NCT04979585
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg ,IV,d1,Q3W.
  • Anlotinib — DRUG
    8mg,oral, d1-14,Q3W.
  • nab-Paclitaxel — DRUG
    260mg/m2,IV,d1,Q3W.

Study Details

To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.

Key Dates

Start date
Jul 15, 2021
Status verified
Jul 2021
Primary completion
Apr 14, 2023
Completion
Aug 14, 2023

Study Design

Enrollment
66 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Patients with untreated advanced mucosal melanoma

Primary Outcome Measure

ORR [ Time Frame: 1 year ]

Central Contacts

Related Studies